KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Payables: 2020-2024

Historic Payables for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $55.0 million.

  • AbCellera Biologics' Payables fell 1.22% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.0 million, marking a year-over-year increase of 8.33%. This contributed to the annual value of $55.0 million for FY2024, which is 10.94% up from last year.
  • Per AbCellera Biologics' latest filing, its Payables stood at $55.0 million for FY2024, which was up 10.94% from $49.6 million recorded in FY2023.
  • AbCellera Biologics' 5-year Payables high stood at $55.0 million for FY2024, and its period low was $20.2 million during FY2020.
  • Moreover, its 3-year median value for Payables was $52.5 million (2022), whereas its average is $52.4 million.
  • Per our database at Business Quant, AbCellera Biologics' Payables spiked by 63.97% in 2022 and then declined by 5.56% in 2023.
  • Over the past 5 years, AbCellera Biologics' Payables (Yearly) stood at $20.2 million in 2020, then spiked by 58.54% to $32.0 million in 2021, then spiked by 63.97% to $52.5 million in 2022, then declined by 5.56% to $49.6 million in 2023, then grew by 10.94% to $55.0 million in 2024.